Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02892383
Other study ID # QoL-MM_OUH
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 27, 2017
Est. completion date December 31, 2025

Study information

Verified date February 2022
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the project is to improve quality of life for multiple myeloma patients in the future.


Description:

Multiple myeloma is an incurable malignancy of the bone marrow and the second most common type of haematological cancer. In Denmark, about 320 patients are diagnosed annually with multiple myeloma, and the cancer often affects older people, but 30 % of the patients living with MM are of working age. The prognosis has improved markedly over the last two decades and is expected to improve further. Systematic monitoring of symptoms, side effects and complications over time outside clinical trials has not been performed yet. Knowledge of the elderly and frail patients´ perspective on the multiple myeloma disease is lacking, and the time after anti-myeloma treatment is left unstudied. A common side effect (up to 55 %) to specific types of anti-myeloma drugs is peripheral neuropathy (nerve injury), which can be temporary or permanent in the form of long-term sequelae of pain and numbness. Information on this side effect from the patients´ perspective is missing. The design of the project is a prospective, population-based, national, longitudinal survey with retrospective data collection from more Danish registers. We will include 800 previously untreated and relapsed multiple myeloma patients at treatment-demanding disease recruited from all Danish haematological departments. At inclusion, demographic data and patient-related prognostic markers will be obtained. The patients will complete four validated QoL instruments (EORTC QLQ-C30, MY20, CIPN20 and SF12v2) at 13 measuring points over a period of 24 months. The questions are concerning cancer and MM symptoms, peripheral neuropathy, other side effects, quality of life and functional capacity of a social, emotional and physical character. This project will provide real-time data collection of the symptoms, side effects, complications and quality of life from the general multiple myeloma patients´ perspective during and after anti-myeloma treatment. It will illuminate the reason for the patients´ high loss of working ability. The findings will be integrated in the future Danish National treatment guidelines, and recommendation for rehabilitation in aspects of shared decision making.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 800
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 110 Years
Eligibility Inclusion Criteria: - Previously untreated or relapsed multiple myeloma patients AND - Treatment demanding multiple myeloma disease Exclusion Criteria: - Inability to understand the Danish language or - Psychic or mental illness that prevents the patient from answering the questions in the questionnaires.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Sygehus Sønderjylland Aabenraa
Denmark Aalborg University Hospital Aalborg
Denmark Aarhus University Hospital Aarhus
Denmark Sydvestjysk Sygehus Esbjerg
Denmark Herlev Hospital Herlev
Denmark Hospitalsenheden Vest Holstebro
Denmark Rigshospitalet København
Denmark Odense University Hospital Odense
Denmark Sjællands Universitetshospital Roskilde
Denmark Vejle Sygehus Vejle

Sponsors (2)

Lead Sponsor Collaborator
Odense University Hospital Danish Myeloma Study Group

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients. a. Description of changes in QoL over time 24 months
Secondary Description of changes in QoL over time, based on PROM for the general population of multiple myeloma patients. To analyse changes in QoL measured by EORTC QLQ-C30 (score 0-100), EORTC QLQ-MY20 (score 0-100) and SF12v2-4-week recall (score 0-100) in relation to disease characteristics:
ISS I-III
Type/-s of anti-myeloma treatment
Side-effects of treatment measured by EORTC QLQ-MY20 (score 0-100) and EORTC QLQ-CIPN20 (score 0-100)
Quality of response: IMWG criteria for first and second line treatment
To analyse changes in QoL measured by EORTC QLQ-C30 (score 0-100), EORTC QLQ-MY20 (score 0-100) and SF12v2-4-week-recall (score 0-100) in relation to patient characteristics:
Myeloma Frailty score (fit, intermediate-fitness and frail)
Karnofsky Performance score scale (0-100%)
Charlson comorbidity Index (0-33) and Freiburger comorbidity index (0-3)
24 months
Secondary Description of the impact of peripheral neuropathy on QoL in the general population of multiple myeloma patients over time, based on PROM. To analyse changes in peripheral neuropathy measured EORTC QLQ-CIPN20 (score 0-100) in relation to
Type/-s of anti-myeloma treatment
Side effect of treatment measured by EORTC QLQ-MY20 (score 0-100).
Quality of response: IMWG criteria for first and second line treatment
To analyse changes in peripheral neuropathy measured by EORTC QLQ-CIPN20 (score 0-100) in relation to - Myeloma frailty score (fitness, intermediate-fitness and frail)
24 months
Secondary Description of the impact of recalibration response shift for interpretation of data from longitudinal QoL studies using PROM for QoL measurement in the general population of previously untreated multiple myeloma patients. Recalibration response shift is a change in the patients internal standard of Measurement and will be measured at a then-test interview 9 months after baseline. Then-test is a retrospective pre-test and will capture recalibration response shift and the true change in QoL. For the pre-test, post-test and then-test the EORTC QLQ-C30 (score 0-100), EORTC QLQ-MY20 (score 0-100), EORTC QLQ-CIPN20 (score 0-100) and SF12v2-4-week recall (score 0-100) will be used. 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1